Dr Virginia Gretton has joined ReFaC, the REACH Facilitiation Company based in Crewe, Cheshire, UK, as technical officer.
Gretton was formerly regulatory manager at Harlan Laboratories, Derbyshire, where she was involved with all aspects of REACH registration and compliance. This covered data gap analysis, testing plans, exposure scenarios, risk assessment, classification and labelling, downstream user interaction, Safety Data Sheet preparation, as well as post-registration support.
In addition, Dr Gretton has held posts in academia and managed clinical research projects. She holds a DPhil in chemistry from the University of York, a BSc in combined science, and a post-graduate certificate in REACH management.
Peter Newport, ReFaC’s company secretary, said: ‘Virginia brings a wealth of practical regulatory experience, skills and technical knowledge to her new role, which will be invaluable in helping and advising clients on all aspects of REACH compliance.’
ReFaC hires Dr Virginia Gretton as technical officer
Has experience with all aspects of REACH registration
You may also like
Manufacturing
![Why CAPA keeps failing and what strong organisations do differently]()
Why CAPA keeps failing and what strong organisations do differently
This white paper examines why CAPA systems often close records without preventing recurrence, tracing breakdowns to investigation quality, risk reasoning, and organisational behaviour rather than procedural gaps. It outlines what differentiates compliant CAPA programmes from those that consistently reduce repeat findings and inspection risk
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
![Beyond FAT and SAT: a practical framework to qualify multivendor pharmaceutical manufacturing lines (part II)]()
Beyond FAT and SAT: a practical framework to qualify multivendor pharmaceutical manufacturing lines (part II)
How a centralised qualification matrix reconciles vendor documentation, integrates risk-based verification and connects commissioning findings with deviation, CAPA and audit-ready evidence
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Regulatory
![Beyond FAT and SAT: a practical framework to qualify multivendor pharmaceutical manufacturing lines (part I)]()
Beyond FAT and SAT: a practical framework to qualify multivendor pharmaceutical manufacturing lines (part I)
Documentation Specialist Snehal Godse explains why unit-level FAT and SAT leave critical multivendor interfaces unverified and proposes a risk-based framework to qualify product transfers, control signals, interlocks, sensors and shared utilities
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
![Research grade to GMP: how peptide quality requirements change as development progresses]()
Research grade to GMP: how peptide quality requirements change as development progresses
This article presents a practical guide to matching peptide characterisation, impurity control, traceability and manufacturing oversight with rising regulatory expectations across preclinical and clinical development
